BR0311976A - Derivados de aril-{4-halogeno-4[(heteroaril-metilamino)-metil]-pip eridin-1-il}-metanona, seu processo de preparação e sua utilização a tìtulo de medicamentos - Google Patents

Derivados de aril-{4-halogeno-4[(heteroaril-metilamino)-metil]-pip eridin-1-il}-metanona, seu processo de preparação e sua utilização a tìtulo de medicamentos

Info

Publication number
BR0311976A
BR0311976A BR0311976-9A BR0311976A BR0311976A BR 0311976 A BR0311976 A BR 0311976A BR 0311976 A BR0311976 A BR 0311976A BR 0311976 A BR0311976 A BR 0311976A
Authority
BR
Brazil
Prior art keywords
piperidin
medicines
aryl
halogen
methyl
Prior art date
Application number
BR0311976-9A
Other languages
English (en)
Other versions
BRPI0311976B8 (pt
BRPI0311976B1 (pt
Inventor
Bernard Vacher
Bernard Bonnaud
Jean-Louis Maurel
Francis Colpaert
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of BR0311976A publication Critical patent/BR0311976A/pt
Publication of BRPI0311976B1 publication Critical patent/BRPI0311976B1/pt
Publication of BRPI0311976B8 publication Critical patent/BRPI0311976B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

"DERIVADOS DE ARIL-{4-HALOGENO-4-[(HETERO-ARIL-METILAMINO)-METIL]-PI PERIDIN-1-IL)-METANONA, SEU PROCESSO DE PREPARAçãO E SUA UTILIZAçãO A TìTULO DE MEDICAMENTOS". A presente invenção refere-se a compostos de fórmula geral (1) na qual X e Y representam um átomo de carbono ligado a um átomo de hidrogênio (CH) ou um átomo de nitrogênio; A representa um radical metila, fluormetila, ciano, hidroxila, metoxila, um átomo de cloro ou um átomo de flúor com a condição no entanto, de que quando A é um radical metila (CH~ 3~), e X e Y representam simultaneamente um átomo de carbono ligado a um átomo de hidrogênio, então, B representa necessariamente um átomo de cloro; B representa um átomo de cloro ou um átomo de flúor; D representa um átomo de hidrogênio, um átomo de cloro, um átomo de flúor, um grupo ciano ou um grupo trifluormetila; E representa um átomo de hidrogênio, de flúor ou de cloro.
BRPI0311976A 2002-06-18 2003-06-18 composto derivado de aril-{4-halogeno-4-[(heteroaril-metilamino)-metil]-piperidin-1-il}-metanona e seu uso na fabricação de medicamentos BRPI0311976B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0207470A FR2840900B1 (fr) 2002-06-18 2002-06-18 Nouveaux derives d'aryl[4-halogeno-4- [(heteroaryl-methylamino)-methyl]-piperidin-1-yl]-methanone, leur procede de preparation et leur utilisation a titre de medicaments
PCT/FR2003/001873 WO2003106449A1 (fr) 2002-06-18 2003-06-18 Nouveaux derives d'aryl-{4-halogeno-4-[heteroaryl-methylamino)-methyl]-piperidin-1-yl}-methanone, leur procede de preparation et leur utilisation a titre de medicaments

Publications (3)

Publication Number Publication Date
BR0311976A true BR0311976A (pt) 2005-03-29
BRPI0311976B1 BRPI0311976B1 (pt) 2015-08-18
BRPI0311976B8 BRPI0311976B8 (pt) 2021-05-25

Family

ID=29595331

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0311976A BRPI0311976B8 (pt) 2002-06-18 2003-06-18 composto derivado de aril-{4-halogeno-4-[(heteroaril-metilamino)-metil]-piperidin-1-il}-metanona e seu uso na fabricação de medicamentos

Country Status (15)

Country Link
US (1) US7547700B2 (pt)
EP (1) EP1539738B1 (pt)
JP (1) JP4699027B2 (pt)
CN (1) CN1308325C (pt)
AT (1) ATE424396T1 (pt)
AU (1) AU2003258816B2 (pt)
BR (1) BRPI0311976B8 (pt)
CA (1) CA2489723C (pt)
DE (1) DE60326468D1 (pt)
ES (1) ES2321927T3 (pt)
FR (1) FR2840900B1 (pt)
HK (1) HK1075452A1 (pt)
MX (1) MXPA05000024A (pt)
WO (1) WO2003106449A1 (pt)
ZA (1) ZA200500467B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2852244B1 (fr) * 2003-03-13 2007-09-07 Pf Medicament Utilisation de derives de pyridin-2-yl-methylamine pour la preparation d'un medicament destine au traitement des symptomes de la douleur chronique d'origine neuropathique ou psychogene
FR2891274B1 (fr) * 2005-09-27 2007-11-23 Pierre Fabre Medicament Sa Procede de preparation du (3-chloro-4-fluoro-phenyl)-(4- fluoro-4-{[(5-methyl-pyrimidin-2-ylmethyl)-amino]-methyl}- piperidin-1-yl)-methanone et nouveaux derives pyrimidiniques intermediaires.
JP2011520975A (ja) * 2008-05-19 2011-07-21 ユニヴァーシティ オブ テネシー リサーチ ファウンデーション，ザ ピリミジンの非古典的カンナビノイド化合物及び関連する使用方法
US8389534B2 (en) * 2008-05-19 2013-03-05 The University Of Tennessee Research Foundation Pyrimidine non-classical cannabinoid compounds and related methods of use
FR2946344B1 (fr) 2009-06-05 2012-05-25 Pf Medicament Nouveaux derives d'aryl-{4-halogeno-4-[aminomethyl]-piperidin-1-yl} methanone, leur procede de preparation et leur utilisation a titre de medicaments
EP2338873A1 (en) 2009-12-22 2011-06-29 Gmeiner, Peter New aminotetraline derivatives
US10626105B2 (en) 2016-09-22 2020-04-21 Auspex Pharmaceuticals, Inc. Deuterium-substituted pyridin- and pyrimidin-2-yl-methylamine compounds
WO2019016357A1 (en) 2017-07-20 2019-01-24 Neurolixis USE OF SELECTIVE 5-HT1A SEROTONIN RECEPTOR AGONISTS TO TREAT THE ADVERSE EFFECTS OF VMAT INHIBITORS
WO2023144166A1 (en) 2022-01-26 2023-08-03 Neurolixis Use of serotonin 5-ht1a receptor agonists to treat diseases associated with sudden unexpected death in epilepsy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN169588B (pt) * 1986-10-07 1991-11-16 Pfizer Hospital Prod
FR2755967B1 (fr) * 1996-11-21 1999-01-29 Pf Medicament Derives de la pyridin-2-yl-methylamine, leur procede de preparation et leur application comme medicaments
FR2784378B1 (fr) * 1998-10-09 2000-12-29 Pf Medicament Nouveaux derives d'aryl-(4-fluoro-4-[(2-pyridin-2-yl- ethylamino)-methyl]-piperidin-1-yl)-methanone, leur procede de preparation et leur utilisation a titre de medicaments
FR2820743B1 (fr) * 2001-02-09 2005-02-25 Pf Medicament Procede et intermediaires de synthese pour la preparation de derives de pyridin-2-yl-methylamine

Also Published As

Publication number Publication date
ZA200500467B (en) 2005-12-28
BRPI0311976B8 (pt) 2021-05-25
HK1075452A1 (en) 2005-12-16
CA2489723C (fr) 2011-08-02
US20060100244A1 (en) 2006-05-11
JP4699027B2 (ja) 2011-06-08
FR2840900A1 (fr) 2003-12-19
AU2003258816A1 (en) 2003-12-31
CN1675194A (zh) 2005-09-28
ES2321927T3 (es) 2009-06-15
WO2003106449A8 (fr) 2005-02-17
JP2005534668A (ja) 2005-11-17
AU2003258816B2 (en) 2008-08-21
EP1539738A1 (fr) 2005-06-15
BRPI0311976B1 (pt) 2015-08-18
CA2489723A1 (fr) 2003-12-24
MXPA05000024A (es) 2005-04-08
DE60326468D1 (de) 2009-04-16
WO2003106449A1 (fr) 2003-12-24
FR2840900B1 (fr) 2005-02-25
ATE424396T1 (de) 2009-03-15
CN1308325C (zh) 2007-04-04
US7547700B2 (en) 2009-06-16
EP1539738B1 (fr) 2009-03-04

Similar Documents

Publication Publication Date Title
HK1075452A1 (en) Novel aryl- 4-halo-4- heteroarylmethylamino)-methyl -piperidin-1-yl - methanone derivatives, methods for production and use thereof as medicaments
NO20082388L (no) Heteroaryl substituerte piperidinderivater som L-CPT1 inhibitorer
WO2004037811A8 (de) Ausgewählte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel
DE50307267D1 (de) Dihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel
RS20050311A (en) Selected cgrp antagonists,method for production and use thereof as medicament
NO20064166L (no) Utvalgte CGRP-antagonister, deres fremstilling og deres anvendelse som medikanmenter
DK1554282T3 (da) Morphinanderivater substitueret i position 14 og deres kvaternære ammoniumsalte, fremstillingsmetode og anvendelse
WO2005000309A3 (en) Chemical compounds
WO2005103037A3 (de) Ausgewählte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel
ATE373009T1 (de) Verfahren zur vorbereitung von telithromycin
NO20064077L (no) Kemokinreseptorantagonister
NO20051600L (no) 1,4-disubstituerte piperidinderivater og anvendelse derav som 11-betaHSD1 inhibitorer
ATE415148T1 (de) Feste pharmazeutische zusammensetzung mit donepezilhydrochlorid
GEP20105071B (en) Processes for preparing 4-(phenoxy-5-methyl-pyrimidin-4-yloxy) piperidine-1-carboxylic acid derivatives and related compounds
ATE349412T1 (de) Epothilon-synthesebausteine i: unsymmetrisch substituierte acyloine und acyloinderivate, verfahren zu deren herstellung sowie deren verwendung zur herstellung von epothilonen und epothilonderivaten
TR200201168T2 (tr) CGRP-Antagonistleri-yeni siklopropanlar içeren ilaçlar ve üretim yöntemleri.
NO20023161L (no) Substituerte piperidiner, legemidler inneholdende disse forbindelser og fremgangsmåter for fremstilling av dem
RS51858B (en) 4 - [(3-FLUOROPHENOXY) PHENYLMETHYL] PIPERIDINE METANSULPHONATE: ITS USES, PROCESSING METHODS AND PHARMACEUTICAL COMPOSITIONS
WO2009034029A3 (de) 1-substituierte 4 -heterocyclylpiperidine als cgrp antagonisten
NO20071754L (no) Biotinylerte heksadekasakkarider, fremstilling og anvendelse derav
ATE525364T1 (de) Verfahren zur herstellung von 3,6-dihydro-1,3,5- triazin-derivaten
NO20082369L (no) Nye vinyloge syrederivater
NO20060605L (no) 2-4-(hydroxymethyl-fenylamino)-piperidin-1-YL!-N-(9H-carbazol-3-YL)-acetamin derivater og beslektede forbindelser som neuropeptid Y5 (NPY5) ligander for behandling av fedme
DE602004010529D1 (de) 2-amino-5-benzoylthiazol npy-antagonisten
MX2008000821A (es) Nuevos derivados de piperidina.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 18/08/2015, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/06/2003 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2779 DE 09-04-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.